Effect of tacrolimus and cyclosporine A on suppression of albumin secretion induced by inflammatory cytokines in cultured human hepatocytes

Li, Y.; Liu, F. Y.; Liu, Z. H.; Huang, Yue; Li, L. S.; Zhang, X.; Peng, Yue

doi:10.1007/s00011-006-0074-0

Cited by 17 publications

(12 citation statements)

References 30 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our secondary outcomes, the results indicate that significant differences in the levels of 24 h UP and serum albumin at the follow-up visit of 6 months. The underlying mechanism may be attributed to the protective effect of TAC on hepatocytes and its inhibitory effect on interleukin-6, which reduce the secretion of hepatic albumin [20]. During the 18month period of treatment, Scr did not wave which is different to previously reported studies [9,21].…”

Section: Discussioncontrasting

confidence: 82%

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy

Zou

Jiang

2019

Renal Failure

View full text Add to dashboard Cite

Background: Guidelines recommend combined therapy of glucocorticoid and cyclophosphamide (CYC) for patients with idiopathic membranous nephropathy (IMN), while it is associated with severe adverse effects. We conducted a retrospective study to evaluate the effectiveness and safety of glucocorticoid plus tacrolimus (TAC) for IMN. Methods: Two hundred and three kidney-biopsy-proven IMN patients were enrolled in this study. One group ( n = 142) received glucocorticoid combined with intravenous CYC (750 mg/m 2 body surface) and the other group ( n = 61) received glucocorticoid combined with oral TAC (target blood concentration of 4–8 ng/mL). The primary outcomes were achievement of remission and incidence of adverse events. The secondary end points included relapse rates, 24 h urinary protein (UP), serum albumin, serum creatinine and estimated glomerular filtration rate. Results: Over the 18-month observation period, the study suggested that the remission rates at the first 3 months were significantly higher in TAC group than in CYC group (72.1% versus 54.9%, p < .05). Although the cumulative incidence of serious and non-serious adverse events was not different significantly between the two groups, the incidence after first 3 months was lower in TAC group. 24hUP and serum albumin improved in TAC group more than the CYC group ( p < .05) over the observed period. Conclusion: Because of its short-term effectiveness and long-term safety profile, glucocorticoid plus TAC might be a better option for IMN.

show abstract

Section: Discussioncontrasting

confidence: 82%

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy

Zou

Jiang

2019

Renal Failure

View full text Add to dashboard Cite

show abstract

“…Elevated IL-6 is correlated with poor survival of lung cancer (30). It is also known that IL-6 inhibits albumin synthesis (31). It is possible that pretreatment mGPS may be a prognostic factor in patients with early-stage NSCLC, because mGPS reflects the systemic status of patients with cancer.…”

Section: Discussionmentioning

confidence: 99%

Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

Kishi

Matsuo

Ueki

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Our finding agreed with a previous study (16). The underlying mechanism might be the protective effect of TAC on hepatocytes and its inhibitory effect on interleukin-6; both actions decrease hepatic albumin secretion (27). …”

Section: Discussionmentioning

confidence: 99%

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy

Cui

Min

et al. 2017

Braz J Med Biol Res

View full text Add to dashboard Cite

We evaluated the efficacy and safety of tacrolimus (TAC) combined with corticosteroids in treating patients with idiopathic membranous nephropathy (IMN). One hundred seventy-seven biopsy-proven IMN patients were recruited in this retrospective clinical study. Sixty patients received TAC (target blood concentration of 4–8 ng/mL) and 117 patients received daily cyclophosphamide (CYC, 100 mg) combined with prednisone. Remission rates at the end of the first, second and third month in the TAC group were significantly higher than that in the CYC group (1st: 35.0 vs 19.7%, P<0.05; 2nd: 56.7 vs 38.5%, P<0.05; 3rd: 76.7 vs 59.0%, P<0.05). In the first 3 months, daily urinary protein and serum albumin in the TAC group obtained a better improvement than that in the CYC group (P<0.05). At the end of the sixth and the twelfth month, the remission rates, daily urinary protein and serum albumin were all comparable between the two groups (P>0.05). No significant difference of relapse rate between the groups was found (16.3 vs 12.0%, P>0.05). Patients were more likely to develop glucose intolerance in the TAC group. The TAC regimen obtained more benefits in treating IMN patients, especially in the first 3 months, than the CYC regimen.

show abstract

Effect of tacrolimus and cyclosporine A on suppression of albumin secretion induced by inflammatory cytokines in cultured human hepatocytes

Abstract: These findings suggest that IL-6, but not IL- 10, may play an important role in the suppression of hepatic albumin secretion. FK506 but not CSA protects against the suppression of hepatic albumin synthesis caused by IL-6.

Cited by 17 publications

References 30 publications

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy

Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy

Contact Info

Product

Resources

About